The phase I clinical trial of the HSP90 inhibitor (SNX-5422) assessed the safety and efficacy of using SNX-5422 along with carboplatin and paclitaxel in patients with advanced lung cancer [228]. The gene discussed is HSP90AA1; the disease is lung carcinoma.